MRI-Guided Ultrasound Stimulated Microbubbles Radiation Treatment for Patients with Chest-Wall and Locally Advanced Breast Cancer
NCT06633601 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2024-10-09
Summary
The objective of this study is to demonstrate the feasibility of novel Magnetic Resonance Imaging (MRI)-guided ultrasound stimulated microbubble treatment to enhance radiation effects in humans receiving external beam radiotherapy delivered using a LINAC (linear accelerator) radiation therapy device.
Conditions
Interventions
- DEVICE
-
MR-Guided Focused Ultrasound Technology
MRI Guidance for use with High-intensity-focused ultrasound (HIFUS)
- DRUG
-
Definity Suspension for Injection
Microbubble contrast agents for ultrasound
Sponsors & Collaborators
-
Terry Fox Research Institute
collaborator OTHER -
Sunnybrook Health Sciences Centre
lead OTHER
Principal Investigators
-
Gregory Czarnota, MD, PhD. · Sunnybrook Health Sciences Centre
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-07-01
- Primary Completion
- 2026-03-01
- Completion
- 2029-03-01
Countries
- Canada
Study Locations
More Related Trials
-
Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC.
NCT06705127 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer
NCT06738966 ·Status: RECRUITING ·Phase: PHASE1
-
An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors
NCT03661632 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors
NCT06503783 ·Status: RECRUITING ·Phase: PHASE1
-
Single-Fraction Very Accelerated Partial Breast Irradiation (sfVAPBI)
NCT07067437 ·Status: RECRUITING ·Phase: NA
-
Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers
NCT00291473 ·Status: COMPLETED ·Phase: PHASE1
-
Phase I Dose Escalation of Single Fraction Adjuvant Stereotactic Body Partial Breast Irradiation Early Stage Breast CA
NCT02685332 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Breast Cancer Study of Preoperative Pembrolizumab + Radiation
NCT03366844 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Abemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer
NCT06344780 ·Status: ACTIVE_NOT_RECRUITING
-
Hypofractionation With Simultaneous Integrated Boost for Early Breast Cancer
NCT04913532 ·Status: COMPLETED ·Phase: NA
-
A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC
NCT06439771 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
NCT06609187 ·Status: RECRUITING ·Phase: PHASE1
-
Study of Irinotecan Liposome Injection in Patients With Advanced Breast Cance
NCT04728035 ·Status: COMPLETED ·Phase: PHASE1
-
A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer
NCT07150767 ·Status: WITHDRAWN ·Phase: PHASE1
-
Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Breast Cancer
NCT03524261 ·Status: WITHDRAWN ·Phase: PHASE2
-
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
NCT06714617 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
NCT06312176 ·Status: RECRUITING ·Phase: PHASE3
-
Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer
NCT03523572 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer
NCT04796623 ·Status: COMPLETED ·Phase: PHASE2
-
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
NCT06239467 ·Status: RECRUITING ·Phase: PHASE1
-
Efficacy and Safety of DEB-BACE With Sequential Arotinib and Tirelizumab in the Treatment of Advanced NSCLC
NCT05380271 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
NCT07047365 ·Status: RECRUITING ·Phase: PHASE3
-
SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC
NCT06627712 ·Status: RECRUITING ·Phase: PHASE3
-
Phase Ib/II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Sunitinib
NCT01070706 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors
NCT07130383 ·Status: RECRUITING ·Phase: PHASE2